newsfilter
← Latest News
Business Wire·

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan's lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to